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Abstract
Background: Adherence to the Mediterranean diet (MD) is associated with reduced morbidity and mortality due to
cardiovascular disease. However, how the MD exerts its effects is not fully known.
Aim: To assess the 12-month effects of two enhanced MDs compared to a low-fat diet on inflammatory biomarkers related
to atherosclerosis and plaque vulnerability in a subcohort of the PREDIMED (Prevencio´n con Dieta Mediterra´nea) study.
Methods: A total of 164 participants at high risk for cardiovascular disease were randomized into three diet groups: MD
supplemented with 50 mL/d of extra virgin olive oil (MD+EVOO) or 30 g/d of nuts (MD+Nuts) and a low-fat diet. Changes in
classical cardiovascular risk factors, inflammatory biomarkers of atherosclerosis and plaque vulnerability were measured
after 12 months of intervention.
Results: Compared to participants in the low-fat diet group, those receiving MD+EVOO and MD+Nuts showed a higher
decrease in systolic (6 mmHg) and diastolic (3 mmHg) blood pressure (P = 0.02; both), as well as a reduction of 10% and 8%
in LDL-cholesterol (P = 0.04), respectively. Patients in the MD+Nuts group showed a significant reduction of 34% in CD40
expression on monocyte surface compared to low-fat diet patients (P = 0.03). In addition, inflammatory biomarkers related
to plaque instability such as C-reactive protein and interleukin-6 were reduced by 45% and 35% and 95% and 90% in the
MD+EVOO and MD+Nuts groups, respectively (P,0.05; all) compared to the low-fat diet group. Likewise, sICAM and P-
selectin were also reduced by 50% and 27%, respectively in the MD+EVOO group (P = 0.04) and P-selectin by 19% in MD+
Nuts group (P = 0.04) compared to the low-fat diet group.
Conclusions: Adherence to the MD is associated with an increase in serum markers of atheroma plaque stability which may
explain, at least in part, the protective role of MD against ischemic heart disease.
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Introduction
Atherosclerosis, the pathological substratum of coronary heart
disease (CHD), is a low-grade chronic inflammatory disease of the
vascular wall initiated by the accumulation of cholesterol-laden
inflammatory cells (monocytes and T-lymphocytes) in the suben-
dothelial space in a self-perpetuating process that leads to the
formation of atheroma plaques, the hallmark of the disease [1].
Inflammatory mediators such as adhesion molecules (selectins,
integrins) and interleukins (e.g., IL-6, IL-1b, IL-18) participate in
this process. In some instances, the atheroma plaque becomes
unstable, leading to cap rupture and ensuing thrombosis that
occludes the artery and finally, induces cardiovascular events such
myocardial infarction or stroke [2]. Some of these inflammatory
mediators (e.g., C-reactive protein [CRP], IL-6, intercellular
adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1
[VCAM-1]) have been considered as useful predictive markers of
atherosclerosis [3], whereas other biomarkers (matrix metallopro-
tease-9 and IL-18) have been associated with plaque vulnerability
[4].
The PREDIMED (Prevencio´n con Dieta Mediterra´nea) study is the
first randomized clinical trial designed to assess the beneficial
effects of the MD on the primary prevention of cardiovascular
diseases in elderly subjects at high cardiovascular risk. Up to now
the PREDIMED study has demonstrated that adherence to the
MD is associated with a reduced incidence of diabetes [5–6], the
metabolic syndrome [7], hypertension [8], and better control of
other cardiovascular risk factors [9–10]. In fact, Estruch et al [11]
have recently reported that a MD intervention reduces the
incidence of cardiovascular events by 30% in subjects at high
cardiovascular risk. However, improvement in classical cardiovas-
cular risk factors associated with the MD intervention could not
fully explain the protective effect of the MD against CHD [11].
Some authors have suggested that, at least in the short term, MD
reduces oxidative stress [12], vascular inflammation [13–14], and
endothelial dysfunction [15], all of which are related to atheroma
plaque formation. Thus, in a previous study we have observed
lower serum concentrations of VCAM-1, ICAM-1, E- and P-
selectin, CRP and IL-6, as well as a down-regulation of adhesion
molecules on T-lymphocyte and monocyte surfaces after 3 months
of MD intervention [10,14,16]. However, whether this effect is
maintained in the long run is unknown. Moreover, little is known
about the effect of the MD on markers of plaque vulnerability.
Therefore, we embarked on a study to assess 1-y changes in
inflammatory biomarkers of atherosclerosis as well as markers of
plaque instability in a free-living population with high risk of CHD
participating in the PREDIMED study.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Subjects and Design
The PREDIMED study is a parallel-group, multicenter,
randomized, controlled 5-year clinical trial aimed to assess the
effects of the MD on the primary prevention of cardiovascular
disease (CVD) (http://www.predimed.es) [17]. Recruitment took
place between October 2003 and January 2009, and the 7447
participants were randomly assigned to one of three interventions
(two Mediterranean diets enriched with extra virgin olive oil
(EVOO) or mixed nuts, and a control low-fat diet). The design,
methodology and eligibility criteria for the PREDIMED study
have been previously described [10–11,17]. Briefly, we recruited
men aged 55 to 80 years and women aged 60 to 80 years with no
previously documented CVD. They were eligible if they had type
2 diabetes, or 3 or more major cardiovascular risk factors
(hypertension, high plasma LDL-cholesterol, low plasma HDL-
cholesterol, overweight or obesity, current smoking, or a family
history of premature coronary heart disease). At baseline and after
12 months of follow-up, the participants filled out a 137-item
validated food frequency questionnaire (FFQ), a 14-item ques-
tionnaire assessing adherence to the MD and the Minnesota
leisure-time physical activity questionnaire. We also recorded
medication use, measured anthropometric parameters and blood
pressure, and collected fasting blood and a spot urine samples, as
described previously [14].
In the current study we screened 193 consecutive potential
participants from October 2003 to November 2004 in a primary
care center associated with the Hospital Clı´nic of Barcelona,
Spain, but 29 did not fulfill the inclusion criteria. Thus, 164 were
finnaly included in this substudy. Main outcome measures were
12-month changes in classical cardiovascular risk factors, and
inflammatory markers predictive of atherosclerosis or related to
plaque instability.
Diets
After two screening visits with the dietician, participants who
fullilled inclusion criteria signed an informed consent and were
randomily assigned in a 1:1:1 ratio to one of three dietary
interventions (MD+EVOO, MD+Nuts or low-fat diet). Random-
ization was performed centrally by means of a computer-generated
random-number sequence. All of the participants had a face-to-
face interview with the dietician and a group session at the baseline
visit and quarterly thereafter. The dietary intervention in the three
treatment groups was delivered by the same dietician as described
[11]. The group sessions were organized separately for each of the
three intervention groups. In each session the 14-point score of
adherence to the MD was the main tool to change dietary habits
for the two MDs, and a similar 9-point score was used in the
participants of the low-fat diet group. The focus in the MD groups
was to change portion sizes and the frequency of intake of the
different foods and to modify cooking methods towards the
traditional MD of Mediterranean countries in the sixties. Thus,
participants in both MD groups were recommended to increase
the intake of vegetables ($2 servings/d), fresh fruit ($3 servings/d),
legumes, nuts, fish or seafood ($3 servings/wk), and the use of olive
oil for cooking and dressings, as previously described [11]. The focus
in the control group was to reduce all types of fat, with particular
emphasis on recommending the consumption of lean meats, low-fat
dairy products, cereals, potatoes, pasta, rice, fruits and vegetables.
All participants were provided with descriptions of seasonal foods,
shopping lists, weekly meal plans and cooking recipes, according to
the their intervention group. Olive oil and nut industry companies
supplied EVOO (50 mL/d) or 30 g/d of walnuts, almonds and
halzelnuts free of charge to the respective MD groups, whereas
those in the control group received small nonfood gifts. The fatty
acid composition of the EVOO and nuts used in the trial is
described elsewhere [10]. No total calorie restriction was advised,
nor was physical activity promoted. From the beginning of the study
all participants were recommended to not use multivitamin or
antioxidant supplements.
Ethics Statement
All participants provided informed consent. Participants had
signed the informed Consent. The Institutional Review Board
(IRB) of the Hospital Clinic (Barcelona, Spain) accredited by the
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US Department of Health and Human Services (DHHS) update
for Federal wide Assurance for the Protection of Human Subjects
for International (Non-US) Institutions #00000738 approved the
study protocol on July, 16, 2002. The protocol was also approved
by the ethical review board of our hospital.
Clinical and Laboratory Measurements
Trained personnel measured weight and height using calibrated
scales and a wall-mounted stadiometer, respectively; waist
circumference was determined midway between the lowest rib
and the iliac crest using an anthropometric tape, and blood
pressure (BP) was measured in triplicate with a validated
semiautomatic oscillometer (Omron HEM-705CP) [10–11]. Sam-
ples of serum, EDTA-plasma, and urine were coded and stored at
280uC until assay. A technician blinded to group allocation
processed peripheral blood mononuclear cells (PBMCs) on the
same day of blood extraction. PBMCs were isolated from whole
blood by Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AC)
density-gradient. The expression of adhesion molecules on the
surface of PBMCs was analyzed via double direct immunofluo-
rescence with the use of commercial monoclonal antibodies
following the manufacturer’s instructions. The adhesion molecules
analyzed were: anti-CD49d (Cytogmos), anti-CD11a and anti-
CD11b (Bender Medsystems), anti-CD40, anti-CD14 and anti-
CD2 monoclonal antibodies (Caltag). Cell counts (5000 events for
T-lymphocytes and 2000 for monocytes) and fluorescence analysis
were performed in a FACSCalibur Flow Cytometer (Becton-
Dickinson) using CellQuest software. Results are expressed as
mean fluorescence intensity (MFI) in arbitrary units.
ELISAs were performed in baseline and 1-year samples at the
end of the study period in thawed plasma with commercial kits for
soluble (s) E- and P-selectin, sVCAM-1, sICAM-1, IL-18, IL-6
(BLK and PelkinElmer Elast Amplification System), IL-10 and
tissular inhibitor of metalloproteases-1 (TIMP-1) (R&D Systems),
MMP-9 (Amersham), and transforming growth factor beta 1
(TGF-b1) (R&D Systems). A technician blinded to group
allocation processed the ELISA kits.
Additional serum analytes determined included fasting glucose
and immunoreactive insulin, total cholesterol, triglycerides, HDL
and LDL-cholesterol, and high-sensitivity CRP, as described
elsewhere [10–11]. In a random sample of 56 participants (34%)
we measured urinary tyrosol and hydroxytyrosol levels (as a
measure of adherence to EVOO consumption recommendations)
and the plasma a-linolenic acid (ALA) proportion (as a measure of
adherence to walnut consumption recommendations), as reported
previously [10]. For all laboratory methods, the intra- and inter-
assay variation coefficients ranged from 1.8 to 8.9% and from 0.9
to 9.9%, respectively.
Figure 1. Flowchart of study participants. The diagram includes detailed information on the excluded participants. Abbreviations: MD,
Mediterranean diet.
doi:10.1371/journal.pone.0100084.g001
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Statistical Analyses
For a parallel design, the sample size was determined with the
ENE 3.0 statistical program (GlaxoSmithKline, Brentford, United
Kingdom) assuming a maximum loss of 10% of participants. To
detect a mean difference of 10 MFI units on the expression of
monocyte CD49d with a conservative standard deviation (SD) of
10, 20 subjects would be needed to complete the study (a
risk = 0.05, power = 0.9). The monocyte expression of CD49d was
considered the primary outcome and used to determine the sample
size, but changes in all endpoints were of equal interest in this
study.
We used descriptive statistics with the mean 6 SD for the
baseline characteristics of the participants. Categorical variables
are expressed as percentages. Variables with a skewed distribution
(Kolmogorov) were transformed to their natural logarithm for
analysis. One-factor analysis of variance or chi-square tests, as
appropriate, were used to determine differences in baseline
characteristics among the three study groups. Changes in all
outcomes were assessed with repeated-measures analysis of
variance for the two factors, diet and time, and their interactions.
Significant interactions were analyzed by the simple effects test
with multiple contrasts of Bonferroni. Within- and between-group
differences are expressed as means and 95% confidence intervals
(CI).
The relationship between monounsaturated acid (MUFA)
intake and inflammatory markers was determined by partial
correlation analysis. All statistical tests were two-tailed, with
significance set at P,0.05. Analyses were performed using the
SPSS, version 18.0 (SPSS Inc., Chicago, IL).
Results
Participant Characteristics
Of the 164 participants finnally included, 55, 55 and 54 were
randomized to a MD supplemented with virgin olive oil, a MD
supplemented with nuts, and a low-fat control diet, respectively.
The retention rates for 1 year follow-up were 100%, 100% and
98.2%, respectively (Figure 1). Table 1 shows the baseline
characteristics of these 164 participants, of whom none were lost to
follow-up. The groups were well balanced regarding demographic
characteristics, adiposity and cardiovascular risk factors. The
medication taken and occupation levels were also similar in the
three groups. Drug regimens did not appreciably change during
the 12-month follow-up.
Cardiovascular Risk Factors
The baseline and 12-month values for the classical cardiovas-
cular risk factors are shown in Table 2. The MD+EVOO and
MD+Nuts groups showed a mean reduction in systolic BP of
6 mmHg (P = 0.02; both) and in diastolic BP of around 3 mmHg
(P = 0.02; both), of 6% and 7% (P = 0.04), respectively, in total-
cholesterol, of 10% and 8% (P = 0.04), respectively, in LDL-
cholesterol, and of 9% and 5% (P = 0.01), respectively in the
cholesterol/HDL-cholesterol ratio. Both MDs showed a decrease
in the waist perimeter (P,0.05; both) of the participants from
baseline.
Adhesion Molecule and CD40 Expression in PBMC
As shown in Table 3, after 12 months of intervention the MD+
EVOO group showed a decrease in CD11a (P,0.001), CD49d
(P,0.004) and CD40 (P,0.001) in peripheral T-lymphocytes. In
Table 1. Baseline characteristics of the participants.1
MD+EVOO (n=55) MD+nuts (n=55) Low-fat diet (n=54)
Age (years) 68.166 67.666 67.466
Men (%) 24 (43.6) 31 (56.4) 22 (40.7)
Family history of CHD (%) 16 (29.1) 9 (16.4) 13 (24.1)
Current smokers (%) 10 (18.2) 11 (20) 11 (20.4)
BMI (kg/m2) 27.963.4 27.863.1 28.563.7
BMI$25 kg/m (%) 47 (85.5) 45 (81.8) 44 (81.5)
Type 2 diabetes (%) 46 (83.6) 44 (80) 37 (68.5)
Hypertension (%) 39 (70.9) 29 (52.7) 37 (68.5)
Dyslipidemia (%) 32 (58.2) 34 (61.8) 38 (70.4)
Medications (%)
ACE inhibitors 11 (20) 12 (21.8) 13 (24.1)
Diuretics 13 (23.6) 6 (10.9) 14 (25.9)
Other antihypertensive agents 10 (18.2) 8 (14.5) 9 (16.7)
Statins 17 (31) 14 (25.5) 10 (18.5)
Other-lipid-lowering agents 4 (7.3) 2 (3.6) 6 (11.1)
Insulin 3 (5.5) 7 (12.7) 3 (5.6)
Oral hypoglycemic drugs 30 (54.5) 25 (45.5) 29 (53.7)
Aspirin or antiplatelet drugs 10 (18.2) 8 (14.5) 5 (9.3)
NSAIDS 6 (10.9) 10 (18.2) 8 (14.8)
1Values are mean 6 SD or n (%). ACE, angiotensin converting enzyme; BMI, body mass index; CHD, coronary heart disease; EVOO, extra virgin olive oil; MD+EVOO,
Mediterranean diet supplemented with extra virgin olive oil; MD+Nuts, Mediterranean diet supplemented with nuts; NSAIDS, Non-steroidal antiinflammatory drugs.
doi:10.1371/journal.pone.0100084.t001
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addition, MD+EVOO showed decreased CD11a, CD11b, CD49d
and CD40 (P,0.001; all) in circulating monocytes.
On the other hand, the MD+Nuts group showed a significant
decrease in CD11a and CD40 of (P,0.00; all) in T- lymphocytes.
For monocytes, the MD+Nuts group showed a significant decrease
in CD11a, CD11b, CD49d and CD40 (P,0.001; all).
Finally, the low-fat diet only showed a significant decrease in
CD11a in T-lymphocytes and a decrease in CD11a and CD11b
expression in circulating monocytes (P,0.001; all).
Circulating Markers of Plaque Instability and other
Inflammatory Biomarkers
Baseline plasma concentrations of inflammatory biomarkers
were similar among groups. As can be observed in Table 4, after
a 12-month intervention the participants allocated to the MD+
EVOO showed a decrease in sVCAM-1 (P,0.02), sICAM-1 (P,
0.001) and sP-selectin (P,0.001) concentrations. Furthermore, the
MD+Nuts group showed a decrease in sVCAM-1 (P,0.001) and
sE-selectin (P,0.002) and sP-selectin of (P,0.007). By contrast,
the serum concentration of sICAM-1 was significantly increased
(P,0.02) in the control group.
Other molecules related to plaque instability (Table 4), such as
CRP and IL-6 (P,0.001; both) and the IL-18/IL-10 ratio (P#
0.04) decreased in the MD+EVOO and MD+nuts groups.
Furthermore, in the MD+nuts group, IL-18 concentration also
decreased (P,0.003). Finally, the control group showed a
significant increase in IL-6 (P,0.001), MMP-9 (P,0.003) and
TGF-b1 (P,0.02) levels. The same group, showed an increase,
albeit no significant, in the MMP-9/TIMP-1 ratio (P,0.003) and
TIMP-1, although the changes were not significant.
None of the groups showed significant Pearson correlation
coefficients between MUFA intake and any of the inflammatory
marker concentrations.
Changes in Food and Nutrient Intake during Follow-up
The self-reported dietary habits of the participants prior to
starting the study were similar among the three groups. Baseline
diets were high in fiber, total fat and MUFA because of a high
baseline consumption of olive oil and marine n3 fatty acids due to
frequent fish intake (Appendix S1 and S2). The saturated fatty
acid (SFA) and v3-polyunsaturated fatty acid (PUFA) content of
the diets was relatively low.
Dietary intervention resulted in favorable changes in food
consumption, mainly in the MD groups (Appendix S1).
Accordimgly, after 12 months these subjects showed a significant
increase in adherence to the MD pattern (P,0.001).
Appendix S2 shows changes in baseline energy and nutrient
intake after the 12-month intervention. At 12 months, the
participants in the MD+EVOO group increased the average
urine concentration of the phenolic compound tyrosol 8.0 ng/mL
(P,0.02) from a baseline value of 61.0 ng/mL, and hydroxytyr-
osol increased 39.0 ng/mL (P,0.04) from a baseline value of
205 ng/mL, while the plasma content of ALA increased 0.14
mol% (P,0.01) from a baseline value of 0.3 mol% in subjects
assigned to the MD+Nuts group. These three parameters were
used as an objective measure of compliance in the MD
intervention diet groups.
Discussion
Higher adherence to a MD intervention supplemented with
EVOO or nuts, for at least 12 months, were associated with a
significant decrease in inflammatory markers related to atheroma
plaque formation and plaque instability, in addition to a reduction
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in BP and plasma LDL-cholesterol concentration [18–19]. All of
these mechanisms may explain, at least in part, the lower
incidence of CHD, stroke and mortality in subjects at high risk
of CVD following a Mediterranean diet as has been recently
demonstrated by the PREDIMED study [11].
In the long term, a decrease of 10 or 5 mmHg in systolic or
diastolic BP, respectively, is associated with a 40% and 30%
reduction in the risk of stroke or myocardial infarction,
respectively [20]. Moreover, a 10% reduction in plasma choles-
terol concentrations has been associated with a 20% reduction in
CHD risk [21].
In the current paper, we observed a significant decrease of
6 mmHg in systolic BP and 3 mmHg in diastolic BP in both MD
groups [10]. This same trend was observed in plasma total-
cholesterol concentrations, with a decrease of 5% for the MD+
EVOO and 8% for the MD+Nuts compared to the control group.
These declines were also similar to those already observed at
3 months for both MDs [10]. Nonetheless, improvements in BP
and the lipid profile can not explain the whole protective action of
the MD against atherosclerosis, thereby suggesting the presence of
alternative effects.
It is well known that atherosclerosis is a chronic low-grade
inflammatory disease of the arterial wall [2]. Thus, modulation of
this inflammatory reaction may be another potential way by which
the MD protects against atherosclerosis. In the current study, we
detected several antiinflammatory effects in the three diets studied,
although they were more intense in subjects allocated to the two
MD interventions. These subjects showed a higher down-
regulation of adhesion molecules in T-lymphocytes and monocytes
compared to those in the control group. Moreover, serum
concentrations of endothelial soluble cell adhesion molecules,
CRP and IL-6 were also lower in subjects following the two MDs
compared to control subjects. These results agree with those
previously published by Castaner et al [28] and Estruch et al [10],
both based in data from PREDIMED trial, in which a sustained
traditional MD supplemented with EVOO or nuts may exert
health benefits through changes in the transcriptomic response of
genes related to cardiovascular risk. Moreover, the IL-18 and IL-
18/IL-10 ratio, which are related to ischemic events in the heart
and brain [29–33], were decreased after the MD+nuts and both
MD interventions, respectively, suggesting a greater stability of
atheroma plaque in patients following a MD diet.
This antiinflammatory effect has already been associated with
different interventions related to a lower incidence of cardiovas-
cular disease such as a diet rich in fruit, vegetables and olive oil
[22], statins [23], moderate alcohol intake [24] or physical activity
[25]. In fact, previous studies have reported that some components
of the MD such as EVOO or nuts may down-regulate
inflammatory markers related to atherosclerosis such as VCAM-
1, ICAM-1, E- and P-Selectin, CRP and IL-6 [26–27].
When we analyzed the possible mechanisms responsible for the
antiinflammatory effect observed in both MD groups, the role of
exercise on immunomodulation is probably residual since no
changes in physical activity were observed in the three groups. In
fact, we only observed a significant increase in physical activity in
the low-fat diet group compared to both MD groups, but
paradoxically this situation was not associated with a greater
antiinflammatory effect as would be expected in this group [25].
Finally, the antiinflammatory effect may be due to a synergistic
action among nutrients from key foods of the MD such as EVOO
or nuts.
Interestingly, the antiinflammatory effect of the MD seems to be
greater and more intense in the mid-term compared to the short-
term [10,14], while the effect on classical cardiovascular risk
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factors was similar, thereby suggesting that the MD exerts its
effects on lipids and blood pressure relatively quickly (at 3 mo),
with the maximum effect on systemic inflammatory biomarkers
being achieved later (at 1 y). Thus, in the short-term the effect on
BP and the lipid profile is higher, whereas in the mid-term the
effect on chronic inflammatory response in the arterial wall is
more pronounced.
The strengths of our study are its design as a randomized
controlled clinical trial, excellent completion rates, good compli-
ance, and the specific inflammatory biomarkers studied, which are
involved in different phases of atheroma plaque formation. Finally,
there is the question as to the clinical relevance of the
antiinflammatory effects of MD. However, the recently published
results of PREDIMED [11] showing lower cardiovascular
morbility and mortality are sufficiently consistent to reject any
doubt about the antiinflammatory effect of the MD. Regarding the
limitations, this study was performed in subjects at high
cardiovascular risk and therefore, the results may not be
generalized to the overall population. Moreover, this study was
limited to classical cardiovascular risk factors and inflammatory
parameters. Thus, we can not exclude other protective effects on
other clinical or biological parameters related to cardiovascular
risk such as markers of arterial structure and function or oxidative
stress.
In summary, the results of our study suggest that the
Mediterranean diet supplemented with EVOO or nuts has a dual
effect on the prevention of cardiovascular disease improving
classical cardiovascular risk factors and also has an intense
antiinflammatory effect. Both of these effects could partially
explain the overall beneficial effect of the MD on the primary
prevention of cardiovascular disease observed in high risk subjects.
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